
Nascent Biotech, Inc.
OTC:NBIO
0.23 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Nascent Biotech, Inc. |
Symbool | NBIO |
Munteenheid | USD |
Prijs | 0.2 |
Beurswaarde | 29,927,398 |
Dividendpercentage | 0% |
52-weken bereik | 0.032 - 0.43 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Sean Carrick |
Website | https://www.nascentbiotech.com |
An error occurred while fetching data.
Over Nascent Biotech, Inc.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)